204 related articles for article (PubMed ID: 17284328)
1. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.
Stewart TJ; Greeneltch KM; Lutsiak ME; Abrams SI
Expert Rev Mol Med; 2007 Feb; 9(4):1-20. PubMed ID: 17284328
[TBL] [Abstract][Full Text] [Related]
2. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
Bhutia SK; Mallick SK; Maiti TK
Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the immune response to treat cancer.
Steer HJ; Lake RA; Nowak AK; Robinson BW
Oncogene; 2010 Dec; 29(48):6301-13. PubMed ID: 20856204
[TBL] [Abstract][Full Text] [Related]
5. How tumours escape mass destruction.
Stewart TJ; Abrams SI
Oncogene; 2008 Oct; 27(45):5894-903. PubMed ID: 18836470
[TBL] [Abstract][Full Text] [Related]
6. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
7. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
8. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
9. Tumour escape: antitumour effectors too much of a good thing?
Pawelec G
Cancer Immunol Immunother; 2004 Mar; 53(3):262-74. PubMed ID: 14685780
[TBL] [Abstract][Full Text] [Related]
10. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
11. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Rivoltini L; Canese P; Huber V; Iero M; Pilla L; Valenti R; Fais S; Lozupone F; Casati C; Castelli C; Parmiani G
Expert Opin Biol Ther; 2005 Apr; 5(4):463-76. PubMed ID: 15934826
[TBL] [Abstract][Full Text] [Related]
12. Immune selection in neoplasia: towards a microevolutionary model of cancer development.
Pettit SJ; Seymour K; O'Flaherty E; Kirby JA
Br J Cancer; 2000 Jun; 82(12):1900-6. PubMed ID: 10864195
[TBL] [Abstract][Full Text] [Related]
13. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment and its role in promoting tumor growth.
Whiteside TL
Oncogene; 2008 Oct; 27(45):5904-12. PubMed ID: 18836471
[TBL] [Abstract][Full Text] [Related]
15. Tumour-released exosomes and their implications in cancer immunity.
Iero M; Valenti R; Huber V; Filipazzi P; Parmiani G; Fais S; Rivoltini L
Cell Death Differ; 2008 Jan; 15(1):80-8. PubMed ID: 17932500
[TBL] [Abstract][Full Text] [Related]
16. Scientific contributions toward successful cancer immunotherapy in The Netherlands.
Melief CJ; Scheper RJ; de Vries IJ
Immunol Lett; 2014 Dec; 162(2 Pt B):121-6. PubMed ID: 25455598
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
18. Surgical implications of tumour immunology.
Somers SS
Ann R Coll Surg Engl; 1996 Mar; 78(2):103-9. PubMed ID: 8678441
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
Zou W
Nat Rev Cancer; 2005 Apr; 5(4):263-74. PubMed ID: 15776005
[TBL] [Abstract][Full Text] [Related]
20. From cancer immunosurveillance to cancer immunotherapy.
Stagg J; Johnstone RW; Smyth MJ
Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
